CLINICAL TRIALS PROFILE FOR ERYC SPRINKLES

All Clinical Trials for Eryc Sprinkles

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00136266 ↗	Adherence With Iron Sprinkles Among High-Risk Infants	Completed	Centers for Disease Control and Prevention	Phase 3	2005-03-01	Compared with iron drops, iron sprinkles supplied for 3 months to high-risk children beginning at age 5-7 months will increase adherence and reduce the rates of anemia and iron deficiency.
NCT00210574 ↗	A Pilot Study of Topiramate in Childhood Absence Epilepsy	Completed	Ortho-McNeil Neurologics, Inc.	Phase 2	2005-03-01	Limited data exist on the effectiveness of antiepileptic drugs for treatment of childhood absence epilepsy. Preliminary data suggest that topiramate may be an effective drug for this condition. The present study is designed to provide further evidence of the potential effectiveness of topiramate for childhood absence epilepsy, as well as preliminary information about a potential target dose for future study.
NCT00210574 ↗	A Pilot Study of Topiramate in Childhood Absence Epilepsy	Completed	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Phase 2	2005-03-01	Limited data exist on the effectiveness of antiepileptic drugs for treatment of childhood absence epilepsy. Preliminary data suggest that topiramate may be an effective drug for this condition. The present study is designed to provide further evidence of the potential effectiveness of topiramate for childhood absence epilepsy, as well as preliminary information about a potential target dose for future study.
NCT00213161 ↗	Using Iron Supplementation to Decrease Iron Deficiency Anemia in Infants and Young Children in India	Completed	The Hospital for Sick Children	N/A	2004-08-01	The purpose of this study is to determine the smallest dose of Sprinkles, a single-serving package of iron and other micronutrients, to treat infants with iron deficiency anemia in India. Results have implications for programs using Sprinkles worldwide because lower doses of iron may have fewer side effects.
NCT00233012 ↗	A Study of the Pharmacokinetics, Safety and Tolerability of Topiramate in Infants (Age 1-24 Months) With Refractory Partial-onset Seizures	Completed	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Phase 1	2005-06-01	The purpose of this study is to evaluate the pharmacokinetics safety and tolerability of topiramate in infants aged 1-24 months with refractory partial-onset seizures. Topiramate is an antiepileptic drug approved for use in adult and pediatric patients (aged 2 to 16 years) with refractory partial onset seizures (POS) with or without secondarily generalized seizures, primary generalized tonic clonic seizures, or Lennox-Gastaut syndrome (LGS).
NCT00379158 ↗	Comparison of the Efficacy and Acceptability of Three Types of Micronutrient Supplements in Ghana	Completed	Nestlé Foundation	Phase 4	2003-10-01	1. At 12 mo of age, all three intervention groups will have significantly better iron and vitamin A status than the NI group. 2. Infants who receive the Foodlet or Nutributter will have significantly greater weight and length gains from 6 to 12 mo and higher indices of vitamin B6, riboflavin and zinc status at 12 mo of age than the infants who receive the sprinkles containing iron and vitamin A only. 3. Infants who receive Nutributter will have significantly greater weight and length gains from 6 to 12 mo and higher indices of vitamin A and essential fatty acid (linoleic, alpha-linolenic and docosahexaenoic, DHA) status at 12 mo of age than the infants who receive the Foodlet or sprinkles.

Clinical Trial Conditions for Eryc Sprinkles

Condition Name

Condition Name for Eryc Sprinkles
Intervention	Trials
Anemia	3
Iron Deficiency	1
Malnutrition	1
Micronutrients	1

Condition MeSH

Condition MeSH for Eryc Sprinkles
Intervention	Trials
Anemia	2
Anemia, Iron-Deficiency	2
Malnutrition	1
Seizures	1

Clinical Trial Locations for Eryc Sprinkles

Trials by Country

Trials by Country for Eryc Sprinkles
Location	Trials
United States	3
Bangladesh	2
India	1
United Kingdom	1

Trials by US State

Trials by US State for Eryc Sprinkles
Location	Trials
Tennessee	2
Massachusetts	1

Clinical Trial Progress for Eryc Sprinkles

Clinical Trial Phase

Clinical Trial Phase for Eryc Sprinkles
Clinical Trial Phase	Trials
Phase 4	1
Phase 3	1
Phase 2	3

Clinical Trial Status

Clinical Trial Status for Eryc Sprinkles
Clinical Trial Phase	Trials
Completed	7
Recruiting	2
Not yet recruiting	1

Clinical Trial Sponsors for Eryc Sprinkles

Sponsor Name

Sponsor Name for Eryc Sprinkles
Sponsor	Trials
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	2
The Hospital for Sick Children	2
Vanderbilt University Medical Center	1

Sponsor Type

Sponsor Type for Eryc Sprinkles
Sponsor	Trials
Other	15
Industry	9
U.S. Fed	2

Clinical Trials, Market Analysis, and Projections for Erythromycin (Eryc)

Introduction

Erythromycin, commonly known by its brand name Eryc, is a bacteriostatic antibiotic belonging to the macrolide class. It is produced by Streptomyces erythreus and is widely used to treat various bacterial infections. Here, we will delve into the current state of clinical trials, market analysis, and future projections for erythromycin.

Clinical Trials and Efficacy

Current Clinical Trials

While there are no specific clinical trials titled "Eryc Sprinkles," erythromycin is continuously being studied in various clinical contexts. For instance, clinical trials often focus on its efficacy in treating specific infections and its pharmacokinetics.

• Pharmacokinetics and Safety: Studies have shown that erythromycin has variable bioavailability depending on the dosage form and whether it is taken with or without food. ERYC capsules, for example, demonstrate better and more reliable absorption when taken in a fasting state compared to non-fasting states[1].

Prophylaxis and Treatment

Erythromycin is used for prophylaxis against certain infections, such as pertussis in exposed susceptible individuals, and for the treatment of primary syphilis and streptococcal infections. It is also used for continuous prophylaxis in adults with a history of rheumatic heart disease[1].

Market Analysis

Global Antibiotic Market

The global antibiotic market, which includes erythromycin, is driven by the increasing prevalence of bacterial infections and the need for effective treatments.

• Market Size: The global antibiotic market is substantial, though specific figures for erythromycin are not isolated. However, the broader antibiotic market is expected to grow due to increasing demand and R&D investments by pharmaceutical companies[3].

Competitive Landscape

The market for erythromycin is competitive, with several pharmaceutical companies producing various formulations of the drug.

• Key Players: Companies such as Mayne Pharma, Valeant International, and Fougera Pharmaceuticals are key players in the erythromycin market, offering different dosage forms like capsules, gels, and ointments[5].

Market Projections

Growth Drivers

The market for erythromycin is expected to grow driven by several factors:

• Increasing Infections: The rising incidence of bacterial infections, particularly in regions with limited healthcare access, will drive the demand for antibiotics like erythromycin.
• R&D Investments: Pharmaceutical companies are increasing their R&D spending to improve drug formulations and efficacy, which will contribute to market growth[3].

Regional Outlook

The market for erythromycin is expected to see significant growth in various regions:

• North America and Europe: These regions have a well-established market for antibiotics, with significant R&D investments. However, growth in these regions may be more stagnant compared to emerging markets[3].
• Asia Pacific: This region is expected to exhibit the fastest growth due to the increasing prevalence of infectious and chronic diseases, coupled with growing healthcare infrastructure[3].

Key Takeaways

• Efficacy and Safety: Erythromycin remains a viable treatment option for various bacterial infections, with ongoing clinical trials focusing on its pharmacokinetics and safety.
• Market Growth: The global market for erythromycin is expected to grow, driven by increasing demand for antibiotics and R&D investments.
• Regional Dynamics: The Asia Pacific region is anticipated to be a significant growth driver due to its rising healthcare needs and infrastructure.

FAQs

What is the primary use of erythromycin?

Erythromycin is primarily used to treat bacterial infections, including respiratory tract infections, skin infections, and sexually transmitted diseases.

How is erythromycin administered?

Erythromycin can be administered orally in capsule or tablet form, or topically as an ointment or gel. It is recommended to take oral doses at least 30 minutes and preferably 2 hours before or after a meal[1].

What are the common side effects of erythromycin?

Common side effects include abdominal discomfort, nausea, diarrhea, and hearing loss with high doses over 2 grams per day[1].

Can erythromycin be used for prophylaxis?

Yes, erythromycin can be used for prophylaxis against certain infections, such as pertussis in exposed susceptible individuals and for continuous prophylaxis against streptococcal infections in adults with a history of rheumatic heart disease[1].

Which companies are key players in the erythromycin market?

Key players include Mayne Pharma, Valeant International, and Fougera Pharmaceuticals, among others[5].

Sources

1. ERYC (erythromycin) - Product Monograph Template - Standard. Health Research Services.
2. Sprinkles Market Size, Share - [2024 To 2032] Growth Report. Business Research Insights.
3. Clinical Trials Market SIZE, SHARE | GROWTH REPORT [2032]. Fortune Business Insights.
4. Pharmacokinetics, Safety and Efficacy of the Selumetinib Granule .... AstraZeneca Clinical Trials.
5. Erythromycin | Drug Information, Uses, Side Effects, Chemistry. PharmaCompass.